We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The statement followed multiple reports about Cannard visiting the White House ... for a national ban after 15 weeks of pregnancy. Eli Lilly will acquire biopharmaceutical firm Morphic Holding ...

Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2024 financial results on Aug. 8, 2024. Lilly will also conduct a conference call that day with the investment community and ...

Branded as Kisunla by drugmaker Eli Lilly, donanemab's approval follows years of setbacks and delays in getting the experimental Alzheimer's treatment to market, despite promising clinical trial ...

While that's definitely a long time ago, there arguably hasn't been the need for Eli Lilly to do one. Until 2018, the stock wasn't even trading above $100. But in the past few years, shares of Eli ...

Pharmaceutical giant Eli Lilly (NYSE: LLY) has gotten off to an incredible start in 2024. The company's diabetes and obesity care treatments, Mounjaro and Zepbound, continue to support ...

The approval comes less than a month after an FDA advisory committee endorsed Eli Lilly's drug, despite questions from advisory committee members about the potential side effects of the drug.

Despite the news, shares of Eli Lilly didn't take off. Much of the enthusiasm behind the stock centers around its promising weight loss and diabetes products. The new drug, Kisunla, has the ...

Despite high market multiples, the Eli Lilly stock has outperformed the S&P 500 Health Care Index YTD, and this might just continue. Strong Q1 2024 performance leading to an upgraded guidance for ...

This post was written by Luke Carberry Mogan. Pharmaceutical giant Eli Lilly (LLY) lost approximately $120 billion in market value this week following an announcement from competitor Viking ...

The Food and Drug Administration on Tuesday approved donanemab for treating Alzheimer’s disease, after clinical studies indicated Eli Lilly’s drug could significantly slow cognitive decline ...